Lymphoid infiltration as a predictor of successful immunotherapy with melanoma
https://doi.org/10.18027/2224-5057-2017-1-61-66
Abstract
Cutaneous melanoma is 1–4% of all cancers. Among all malignant skin tumors, melanoma has a special place, it accounts for about 4% of all forms of skin cancer, but 80% of deaths in the group of malignant tumors of the skin caused by melanoma. In 2014 in Russian Federation, the standardized death rate from melanoma of the skin was 1.51 per 100 000 population. The incidence of melanoma has been steadily growing in Russian Federation and many other countries. In absolute increase the incidence of all malignant tumors, skin melanoma is ranked 2nd after lung cancer. Increased incidence of melanoma necessitates in-depth study of the biology of this tumor and its interaction with the immunobiological control system. Considering the immunogenicity of melanoma, the importance of the nature of the immune response to growing tumor. Therefore, one of the most important prognostic factor of the disease in these patients is the severity and subpopulations of lymphoid infiltration of the tumor, which is also important for the selection of personalized
treatments with modern immunotherapeutic drugs, such as ipilimumab, which is the biological target for T cell suppressor receptor CTLA- 4.
treatments with modern immunotherapeutic drugs, such as ipilimumab, which is the biological target for T cell suppressor receptor CTLA- 4.
About the Authors
K. S. TITOV
Moscow Clinical Research Centr,N. I. Pirogov Russian National Research Medical University
Russian Federation
MD, RhD, DSc, head of the Оnсоsurgery Department tumors of skin and soft fabrics, asistant professor of the Department of Oncology and Radiation Therapy
Russian Federation
MD, RhD, DSc, head of the Оnсоsurgery Department tumors of skin and soft fabrics, asistant professor of the Department of Oncology and Radiation Therapy
O. I. CHIKILEVA
N. N. Вlokhin Russian Сancer Research Centre
Russian Federation
MD, RhD, researcher of laboratory of cellular immunity
Russian Federation
MD, RhD, researcher of laboratory of cellular immunity
M. V. KISELEVSKIY
N. N. Вlokhin Russian Сancer Research Centre
Russian Federation
MD, RhD, DSc, professor, head of the laboratory of cellular immunity
Russian Federation
MD, RhD, DSc, professor, head of the laboratory of cellular immunity
A. M. KAZAKOV
N. I. Pirogov Russian National Research Medical University,
Russian Federation
student
Russian Federation
student
References
1. Титов К. С., Михеева О. Ю., Казаков А. М.,Егорова А. В. Роль хирургии в лечении отдаленных метастазов меланомы. Злокачественные опухоли. – 2016. – № 3. – С. 25–31. Titov K. S., Mikheeva O. Y., Kazakov A. M., Egorova A. V. The role of surgery in the treatment of distant metastases of skin melanoma. – Malignant Tumours – 2016; 3: 25–31.
2. Daniela Planska, Monika Burocziova, Jan Strnadel, Vratislav Horak. Immunohistochemical Analysis of Collagen IV and Laminin Expression in Spontaneous Melanoma Regressionin the Melanoma-Bearing Libechov Minipig. Acta Histochem Cytochem. 2015 Feb 28; 48(1): 15–26.
3. Richard Wu, Marie-Andree Forget, Jessica Chacon, Chantale Bernatchez, etc. Adoptive T-cell Therapy Using Autologous Tumor-infiltrating Lymphocytes for Metastatic Melanoma: Current Status and Future. Cancer J. 2012 Mar; 18(2): 160–175.
4. Burton A. L., Roach B. A., Mays M. P., etс. Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg 2011 Feb 77:188–192.
5. Nancy E., Thomas, Klaus J. Busam, etc. Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. J Clin Oncol. 2013 Nov 20; 31(33):4252–9.
6. Grotz T. E., Vaince F., Hieken T. J. Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes. Melanoma Res. 2013 Apr; 23(2):132–7.
7. Farhad Azimi, Richard A. Scolyer, Pavlina Rumcheva, etc. Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. J Clin Oncol. 2012 Jul 20; 30(21):2678–83.
8. Chang W. Y. Complete spontaneous regression of cancer: four case reports, review of literature, and discussion of possible mechanisms involved. Hawaii Med J. 2000; 59: 379–387.
9. Dirk M., Elston M. D. Mechanisms of Regression. Clin Med Res. 2004 May; 2(2): 85–88.
10. Nayeon Choi, Jae Keun Cho, Chung-Hwan Baek, etc. Spontaneous regression of metastatic cancer cells in the lymph node: a case report. BMC Res Notes. 2014 May 13; 7: 293.
11. Martin C. Mihm Jr and James J. Mul . Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response. Cancer Immunol Res August 2015, 3; 827.
12. Matzinger P., Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol. 2011 Mar; 11 (3):221– 30.
13. Zheleznikova G. F. Regulatory t cells in immune response to infection. Journal Infectology. 2011; 3(1):6–13.
14. Bonnelykke-Behrndtz M.L., Steiniche T., Damsgaard T. E., etc. MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with denseinfiltration of CD163 macrophages and loss of E-cadherin. Melanoma Res. 2015 Apr; 25(2):113–8.
15. Lund A. W., Medler T. R., Leachman S. A., Coussens L. M. Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer. Cancer Discov. 2016 Jan; 6(1):22–35.
16. Hadrup S., Donia M., Thor Straten P. Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. Cancer Microenviron. 2013 Aug; 6(2):123–33.
17. K hler K. C., Hassel J. C., Heinzerling L. Management of side effects of immune checkpoint blockade by anti-CTLA‑4 and anti-PD‑1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016 Jul; 14:662–81.
18. Gabriel E. M., Lattime E. C. Anti-CTL-associated antigen 4: are regulatory T cells a target? Clin Cancer Res. 2007 Feb 1; 13(3):785–8.
19. Hoos A., Ibrahim R., Korman A., Abdallah K., Berman D., etc. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010 Oct; 37(5):533–46.
20. Maio M., Grob J. J., Aamdal S., Bondarenko I., Robert C., etc. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. J Clin Oncol. 2015 Apr 1; 33(10):1191–6.
21. Tao Wang, Rajasekharan Somasundaram, Meenhard Herlyn. Combination Therapy of Immunocytokines with Ipilimumab: A Cure for Melanoma? J Invest Dermatol. 2013 Mar; 133(3):595–6.
22. Sapna Pradyuman Patel, Denai Milton, Mohammed M. Milhem, Lawrence E. Flaherty, etc. Sequential administration of high-dose interleukin‑2 and ipilimumab in patients with metastatic melanoma. Journal of Clinical Oncology, 2016 ASCO Annual Meeting (June 3–7, 2016). – 2016 American Society of Clinical Oncology.
23. Howard Kaufman, Jiafeng Wang, Brendan D. Curti, Joseph Clark, Marc S. Ernstoff, etc. A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL‑2 in patients with unresectable stage III and IV melanoma. Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 – June 2, 2015). 2015 American Society of Clinical Oncology.
24. Peter A. Prieto, James C. Yang, Richard M. Sherry, etc. CTLA‑4 Blockade with Ipilimumab: Long-Term Follow-up of 177 Patients with Metastatic Melanoma. Clin Cancer Res. 2012 Apr 1; 18(7):2039–47.
25. Van der Merwe P. A., Bodian D. L., Daenke S., Linsley P., Davis S. J. CD80 (B7–1) binds both CD28 and CTLA‑4 with a low affinity and very fast kinetics. J Exp Med (1997) 185:393–403.
26. Pentcheva-Hoang T., Egen J. G., Wojnoonski K., Allison J. P. B7–1 and B7–2 selectively recruit CTLA‑4 and CD28 to the immunological synapse. Immunity. 2004 Sep; 21(3):401–13.
27. Read S., Greenwald R., Izcue A., Robinson N., Mandelbrot D., Francisco L. et al. Blockade of CTLA‑4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol. 2006 Oct 1; 177(7):4376–83.
28. Shunsuke Chikuma, Abul K. Abbas and Jeffrey A. Bluestone. B‑7-Independent Inhibition of T Cells by CTLA‑4. The Journal of ImmunologyJuly 1, 2005 vol. 175 no. 1, 177–181.
29. Tivol E. A., Borriello F., Schweitzer A. N., Lynch W. P., Bluestone J. A., Sharpe A. H. Loss of CTLA‑4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA‑4. Immunity (1995) 3:541–7.
30. Khattri R., Auger J. A., Griffin M. D. et al. Lymphoproliferative disorder in CTLA‑4 knockout mice is characterized by CD28- regulated activation of Th2 responses. J Immunol. 1999; 162: 5784–5791.
31. Chambers C. A., Sullivan T. J., Allison J. P. Lymphoproliferation in CTLA‑4-deficient mice is mediated by costimulation-dependent activation of CD4+T cells. Immunity (1997) 7:885–95.
32. Friedline R. H., Brown D. S., Nguyen H., Kornfeld H., Lee J., Zhang Y. et al. CD4+regulatory T cells require CTLA‑4 for the maintenance of systemic tolerance. J Exp Med (2009) 206:421–34.
33. Linsley P. S., Bradshaw J., Greene J., Peach R., Bennett K. L., Mittler R. S. Intracellular trafficking of CTLA‑4 and focal localization towards sites of TCR engagement. Immunity. 1996; 4(6):535–543.
34. Fife B. T., Guleria I., Gubbels Bupp M., Eagar T. N., Tang Q., Bour-Jordan H., Yagita H., Azuma M., Sayegh M. H., Bluestone J. A. Insulin-induced remission in new-onset NOD mice is maintained by the PD‑1-PD-L1 pathway. J Exp Med. 2006; 203:2737–47.
35. Hodi F. S., O’Day S.J., McDermott D.F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., van den Eertwegh A. J., etc. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010.
Review
For citations:
TITOV K.S., CHIKILEVA O.I., KISELEVSKIY M.V., KAZAKOV A.M. Lymphoid infiltration as a predictor of successful immunotherapy with melanoma. Malignant tumours. 2017;(1):61-66. (In Russ.) https://doi.org/10.18027/2224-5057-2017-1-61-66
Views:
25451
Email this article 